Table 2 Scenario analyses on relative efficacy of diclofenac
| Â | Placebo | Celecoxib | Naproxen | Etoricoxib | Ibuprofen | Acetaminophen | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scenario 4 (dose ranges) | Diff CFB (95% CrI) | Prob. DCF better | Diff CFB (95% CrI) | Prob. DCF better | Diff CFB (95% CrI) | Prob. DCF better | Diff CFB (95% CrI) | Prob. DCF better | Diff CFB (95% CrI) | Prob. DCF better | Diff CFB (95% CrI) | Prob. DCF better |
Pain VAS 6 weeks | −13.7 (−16.9; −10.5) | >99% | −4.9 (−8.3; 1.4) | >99% | −3.1 (−7.1; 0.9) | 94% | 1.6 (−2.5; 5.6) | 23% | −1.3 (−6.7; 4.1) | 68% | −9.5 (−14.8; −4.1) | >99% |
Pain VAS 12 weeks | −10.1 (−13.2; −7.0) | >99% | −2.6 (−5.8; 0.5) | 95% | −0.9 (−4.2; 2.3) | 70% | 0.4 (−3.4; 4.0) | 42% | −1.6 (−5.8; 2.6) | 77% | −7.1 (−16.0; 1.7) | 94% |
Pain Likert 6 weeks | −1.8 (−2.3; −1.2) | >99% | −0.4 (−1.0; 0.2) | 90% | −0.3 (−1.1; 0.5) | 77% | NA | NA | NA | NA | NA | NA |
Pain Likert 12 weeks | −2.3 (−3.4; −1.2) | >99% | −1.2 (−2.3; 0.0) | 98% | −1.1 (−2.2; 0.0) | 97% | NA | NA | NA | NA | NA | NA |
PF VAS 6 weeks | −10.0 (−15.8; −4.4) | >99% | −1.2 (−7.3; 4.6) | 66% | 0.8 (−5.4; 6.7) | 40% | 1.2 (−4.4; 6.5) | 33% | −1.0 (−7.6; 5.3) | 63% | −6.7 (−15.1; 1.2) | 95% |
PF VAS 12 weeks | −4.5 (−11.9; 2.8) | 89% | 2.3 (−5.3; 10.0) | 27% | 5.9 (−1.9; 13.6) | 7% | 5.3 (−2.4; 13.0) | 9% | 3.1 (−5.3; 11.4) | 23% | −7.1 (−14.2; 0.1) | 97% |
PF Likert 6 weeks | −6.7 (−9.1; −4.4) | >99% | −2.2 (−4.5; 0.2) | 96% | −3.2 (−6.2; −0.2) | 98% | NA | NA | NA | NA | NA | NA |
PF Likert 12 weeks | −7.7 (−10.7; −4.7) | >99% | −3.8 (−6.9; −0.7) | >99% | −3.6 (−6.7; −0.5) | 99% | NA | NA | NA | NA | NA | NA |
PGA VAS 6 weeks | −16.6 (−24.3; −9.0) | >99% | −7.1 (−15.1; 0.8) | 96% | −7.0 (−15.3; 1.3) | 95% | −4.3 (−12.4; 3.8) | 85% | −5.3 (−13.9; 3.3) | 89% | NA | NA |
PGA VAS 12 weeks | −14.1 (−21.4; −6.8) | >99% | −6.6 (−14.1; 0.9) | 96% | −4.6 (−12.4; 3.0) | 89% | −2.4 (−10.0; 5.2) | 74% | −5.5 (−14.1; 3.1) | 90% | NA | NA |
PGA Likert 6 weeks | −0.5 (−0.7; −0.3) | >99% | −0.2 (−0.4; −0.1) | >99% | −0.1 (−0.2; 0.1) | 76% | NA | NA | NA | NA | NA | NA |
PGA Likert 12Â weeks | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Scenario 5 (effect sizes) | Diff CFB (95% CrI) | Prob. DCF better | Diff CFB (95% CrI) | Prob. DCF better | Diff CFB (95% CrI) | Prob. DCF better | Diff CFB (95% CrI) | Prob. DCF better | Diff CFB (95% CrI) | Prob. DCF better | Diff CFB (95% CrI) | Prob. DCF better |
Pain 6 weeks | −0.7 (−0.9; −0.4) | >99% | −0.3 (−0.5; 0.0) | 98% | −0.2 (−0.5; 0.1) | 92% | 0.0 (−0.3; 0.3) | 54% | −0.1 (−0.4; 0.2) | 75% | −0.5 (−0.8; −0.1) | >99% |
Pain 12 weeks | −0.5 (−0.7; −0.3) | >99% | −0.2 (−0.4; 0.0) | 98% | −0.2 (−0.4; 0.0) | 95% | −0.1 (−0.3; 0.1) | 70% | −0.2 (−0.4; 0.1) | 94% | −0.4 (−0.8; 0.1) | 93% |
PF 6 weeks | −0.5 (−0.6; −0.3) | >99% | −0.1 (−0.3; 0.1) | 87% | 0.0 (−0.2; 0.2) | 51% | 0.0 (−0.2; 0.2) | 51% | −0.1 (−0.3; 0.1) | 83% | −0.3 (−0.5; 0.0) | 98% |
PF 12 weeks | −0.4 (−0.9; 0.2) | 90% | −0.1 (−0.6; 0.5) | 60% | 0.1 (−0.5; 0.6) | 42% | 0.0 (−0.5; 0.6) | 44% | 0.0 (−0.6; 0.5) | 55% | −0.6 (−1.1; 0.0) | 98% |
PGA 6 weeks | −0.8 (−0.9; −0.6) | >99% | −0.2 (−0.4; −0.1) | >99% | −0.3 (−0.5; −0.1) | >99% | −0.2 (−0.4; −0.1) | >99% | −0.4 (−0.6; −0.2) | >99% | NA | NA |
PGA 12Â weeks | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |